How Corbus Uses Synthetic Cannabinoids to Fight Diseases
| Bloomberg

Yuval Cohen, Corbus Pharmaceuticals chief executive officer, discusses how the company is combating autoimmune diseases with Bloomberg’s Ed Hammond on “Bloomberg Markets: The Close.”

What’s Next for Bioresorbable Scaffolds?

Abbott Laboratories presented some disappointing data for its bioresorbable stent program at TCT, but it was a different story for Reva Medical’s scaffold.

United Neuroscience Continues Growth with Addition of Five Executives to Management Team

United Neuroscience, Ltd., (UNS), a clinical-stage biotech company pioneering a new class of medicine to treat and prevent brain disorders, today announced five executive appointments as part of the company’s continued expansion of the management team.